168 related articles for article (PubMed ID: 27631094)
1. Psychological impact of serial prostate-specific antigen tests in Japanese men waiting for prostate biopsy.
Kobayashi M; Nukui A; Kamai T
Int J Clin Oncol; 2017 Feb; 22(1):174-180. PubMed ID: 27631094
[TBL] [Abstract][Full Text] [Related]
2. Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.
Brindle LA; Oliver SE; Dedman D; Donovan JL; Neal DE; Hamdy FC; Lane JA; Peters TJ
BJU Int; 2006 Oct; 98(4):777-82. PubMed ID: 16978272
[TBL] [Abstract][Full Text] [Related]
3. Psychological distress and prostate specific antigen levels in men with and without prostate cancer.
Turner EL; Lane JA; Metcalfe C; Down L; Donovan JL; Hamdy F; Neal D; Vedhara K
Brain Behav Immun; 2009 Nov; 23(8):1073-8. PubMed ID: 19486654
[TBL] [Abstract][Full Text] [Related]
4. Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA) - Results from a prospective, population-based, randomised study.
Carlsson S; Aus G; Wessman C; Hugosson J
Eur J Cancer; 2007 Sep; 43(14):2109-16. PubMed ID: 17643983
[TBL] [Abstract][Full Text] [Related]
5. Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?
Macefield RC; Lane JA; Metcalfe C; Down L; Neal DE; Hamdy FC; Donovan JL
Eur J Cancer; 2009 Sep; 45(14):2569-73. PubMed ID: 19375907
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen (PSA) and distress: - a cross-sectional nationwide survey in men with prostate cancer in Sweden.
Rönningås U; Fransson P; Holm M; Wennman-Larsen A
BMC Urol; 2019 Jul; 19(1):66. PubMed ID: 31299962
[TBL] [Abstract][Full Text] [Related]
7. Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result.
Macefield RC; Metcalfe C; Lane JA; Donovan JL; Avery KN; Blazeby JM; Down L; Neal DE; Hamdy FC; Vedhara K;
Br J Cancer; 2010 Apr; 102(9):1335-40. PubMed ID: 20372151
[TBL] [Abstract][Full Text] [Related]
8. Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease.
Freedland SJ; Mangold LA; Epstein JI; Partin AW
Urology; 2004 May; 63(5):887-91. PubMed ID: 15134972
[TBL] [Abstract][Full Text] [Related]
9. Impact of prostate cancer screening on health-related quality of life in at-risk families.
Cormier L; Guillemin F; Valéri A; Fournier G; Cussenot O; Mangin P; Litwin MS
Urology; 2002 Jun; 59(6):901-6. PubMed ID: 12031378
[TBL] [Abstract][Full Text] [Related]
10. The psychological impact of prostate biopsy: Prevalence and predictors of procedure-related distress.
Sharp L; Morgan E; Drummond FJ; Gavin A
Psychooncology; 2018 Feb; 27(2):500-507. PubMed ID: 28766309
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.
Berger AP; Deibl M; Steiner H; Bektic J; Pelzer A; Spranger R; Klocker H; Bartsch G; Horninger W
Prostate; 2005 Aug; 64(3):240-5. PubMed ID: 15712213
[TBL] [Abstract][Full Text] [Related]
12. Repeat Prostate-Specific Antigen Tests Before Prostate Biopsy Decisions.
Nordström T; Adolfsson J; Grönberg H; Eklund M
J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27418620
[TBL] [Abstract][Full Text] [Related]
13. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
[TBL] [Abstract][Full Text] [Related]
14. Does obesity affect the accuracy of prostate-specific antigen (PSA) for predicting prostate cancer among men undergoing prostate biopsy.
Oh JJ; Jeong SJ; Lee BK; Jeong CW; Byun SS; Hong SK; Lee SE
BJU Int; 2013 Aug; 112(4):E265-71. PubMed ID: 23432960
[TBL] [Abstract][Full Text] [Related]
15. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
[TBL] [Abstract][Full Text] [Related]
16. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam).
Roobol MJ; van der Cruijsen IW; Schröder FH
Urology; 2004 May; 63(5):892-7; discussion 897-9. PubMed ID: 15134973
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R
BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645
[TBL] [Abstract][Full Text] [Related]
18. Prostatic transition zone biopsies in men with previous negative biopsies and persistently elevated serum prostate specific antigen values.
Keetch DW; Catalona WJ
J Urol; 1995 Nov; 154(5):1795-7. PubMed ID: 7563349
[TBL] [Abstract][Full Text] [Related]
19. Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging.
Coakley FV; Chen I; Qayyum A; Westphalen AC; Carroll PR; Hricak H; Chen MH; Kurhanewicz J
BJU Int; 2007 Jan; 99(1):41-5. PubMed ID: 17227490
[TBL] [Abstract][Full Text] [Related]
20. Are repeat biopsies required in men with PSA levels < or =4 ng/ml? A Multiinstitutional Prospective European Study.
Djavan B; Fong YK; Ravery V; Remzi M; Horninger W; Susani M; Kreuzer S; Boccon-Gibod L; Bartsch G; Marberger M
Eur Urol; 2005 Jan; 47(1):38-44; discussion 44. PubMed ID: 15582247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
